ElevateBio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

#3476

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • ElevateBio's estimated annual revenue is currently $60M per year.(i)
  • ElevateBio's estimated revenue per employee is $155,000
  • ElevateBio's total funding is $845M.

Employee Data

  • ElevateBio has 387 Employees.(i)
  • ElevateBio grew their employee count by 99% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

A New Model To Accelerate Innovation ElevateBio is creating and operating a portfolio of cell and gene therapy companies through partnerships with the worldᅢᄁ¬ツᆲ¬トᄁs most innovative scientists and inventors. Together, we leverage our internal bench-to-bedside expertise to accelerate the development and delivery of therapies ᅢᄁ¬ツᆲ¬タワ supported by our broad access to capital. Many Companies ᅢᄁ¬ツᆲ¬タワ One Robust Organization ElevateBioᅢᄁ¬ツᆲ¬トᄁs novel business model, including BaseCamp, our centralized R&D and manufacturing organization, is structured to rapidly and efficiently build single- and multi-product cell and gene therapy companies. Each portfolio company benefits from our fully-integrated capabilities, including basic and translational research, process development, cGMP manufacturing, clinical development, regulatory affairs and commercial operations.

keywords:N/A

$845M

Total Funding

387

Number of Employees

$60M

Revenue (est)

99%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ElevateBio News

2022-04-20 - AlloVir Gains Third RMAT Designation For Antiviral T Cell ...

With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new...

2022-04-17 - Biotech venture capital: Top 10 money-raisers of 2021

Late last year, ElevateBio bought a former partner, Life Edit Therapeutics, gaining access to Life Edit's genome editing platform. The biotech...

2022-04-13 - TREEFROG THERAPEUTICS EXPANDS BOARD WITH NEW ...

Melissa Carpenter, PhD, Chief Scientific Officer of US-based cell & gene therapy biotech ElevateBio's Regenerative Medicine unit,...

2021-03-18 - ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 18, 2021-- ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the company’s Chief Scientific Officer of Regenerative Medicine, Dr. Melissa Carpenter, has been appointed to ...

2021-03-16 - ElevateBio collects $525M Series C

ElevateBio has raised $525 million in a round led by Matrix Capital Management, with participation from investors including SoftBank's Vision Fund 2 and Fidelity Management & Research. Based in Massachusetts, the company is a developer of cell, gene and regenerative therapies. Select Additional ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$56.1M387N/AN/A
#2
$120.9M398-2%N/A
#3
$139.1M4125%N/A
#4
$91.4M4155%$714M
#5
$115M4182%N/A